Previous studies suggesting immunotherapy directed at PD-1 as a suitable treatment option for glioblastoma are based on the presence of PD-L1 in tumour tissue [6, 7], and the success of anti-PD-1 in preclinical models [26, 39]. The gene discussed is PDCD1; the disease is glioblastoma.